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lost one of the great Biochemists of his
generation a few months from his 60th
birthday. Dr. Ju¨rg Tschopp grew up in
Basel in his beloved Switzerland. As a
youth, he proved to be a gifted athlete.
He was nationally recognized in the de-
cathlon and, naturally, growing up a mere
stones-throw from the Alps was a formi-
dable skier. I discovered this—largely to
my peril. Several times at many a meeting
over the years, I unwisely attempted to
follow his lead down one too many ‘‘chal-
lenging’’ slopes with sobering effect.
Of the many memories of my interac-
tions with Ju¨rg, I recall with genuine affec-
tion our jousting in Swiss German with my
limited, although colorful, vocabulary of
around 20 words, acquired when I was
a postdoc in Zurich years earlier. Those
discussions were brief but nevertheless
memorable. It was always clear to me
that Ju¨rg possessed a powerful combina-
tion of fearlessness, rigor, and excellence,
three characteristics that are central to
being a great scientist. Thus, his many
contributions throughout a brilliant career
came, in a way, as no surprise.
Ju¨rg received rigorous training as an
undergraduate in chemistry and as a
graduate student in biophysics at the
renowned Biocentrum of the University
of Basel, obtaining his PhD in Biophysics
in 1979. Immunology caught his attention,
and he decided to perform postdoctoral
studies under the mentorship of Dr. H.J.
Mu¨ller-Eberhard at the Scripps Clinic in
La Jolla, CA. There, he did important
work, showing that the lytic pore of
complement was formed by C9 multi-
mers. He continued in the complement
field and in 1982 returned to his position
as Assistant Professor at the Institute of
Biochemistry at the Institute of Lausanne.
During the early period of his work in
Switzerland he published extensively
and in part shifted his research direction
to the nature of the lytic components of
cytotoxic T lymphocytes (CTLs). His inter-
ests in these involved the study of the
so-called granzymes, serine proteasesthat play a role in the CTL process. He
cloned the genes of several granzymes
and characterized their encoded proteins
isolated from granules from cloned CTLs.
This work on granzymes complemented
his earlier work, in which he characterized
a lytic pore-forming component, perforin,
which mediates killing by CTL. Ju¨rg’s
work was influential in establishing the
function of these molecules and in
describing the acquisition of these cyto-
lytic granules upon the induction of cyto-
lytic activity in CTL. His work on these
cytotoxic molecules was recognized not
only in a substantial number of primary
research publications in prominent immu-
nologic journals but also in an influential
review published in 1990 in the Annual
Reviews of Immunology. His interest in
this area led naturally to Ju¨rg posing the
question of whether perforin was the only
pathway toward lysis, or whether other
pathways played a role. Addressing this
issue, in 1994 he published an important
paper in which he showed that cytolytic
T cell cytotoxicity is mediated through
two lytic pathways, perforin and fas. This
paper, published in Nature, establishedCellthis important point and therefore brought
Ju¨rg significant recognition.
The importance of fas in cell death led
Ju¨rg to develop an interest in apoptosis,
and in the course of this he contributed
importantly to several aspects of the study
of apoptosis. He was a regular invited
speaker at essentially all the prominent
apoptosis meetings. Ju¨rg published
some highly important papers on the
regulation of the apoptotic pathway
following fas ligation and ligation of other
TNF receptor family members. Of these
papers, several were outstanding. First,
he discovered in 1997 that a viral FLICE
inhibitory protein (FLIP) was able to
prevent apoptosis mediated through the
above-mentioned death receptors. This
was an important observation for it
suggested first that negative regulatory
mechanisms existed and second that
pathogens abuse such mechanisms in
order to subvert host defense mecha-
nisms. In a natural extension of this work,
again in a highly influential paper in 1997,
Ju¨rg identified the cellular homolog of the
viral protein as cellular or c-FLIP. This
paper led to an understanding of this
important class of molecules whose func-
tions include inhibition of cell death but, in
addition, was shown to play interesting
roles in positive signaling mechanisms
downstream of death receptors. Specifi-
cally, his work in collaboration with Ralph
Budd led to the fascinating observation
that FLIP played a role in T cell prolifera-
tion. They first showed, in 1999, that cas-
pases were required for T cell proliferation
and then went on to show that FLIP was
able to activate NF-kB and Erk pathways.
He extended his work to numerous other
death receptor families. Ju¨rg’s interest
in apoptosis and death receptors led
naturally to a focusing of his attention to
other members of the TNF family. Using
bioinformatics, he identified several new
members including BAFF, a novel ligand
of this family that stimulates B cell growth.
It is now clear that BAFF is one of the
most important B cell proliferation and
differentiation factors and, like several
other molecules he identified, is now
a significant clinical target.
Perhaps Ju¨rg’s greatest contributions
were his studies on a family of intracellular
innate immune sensors that play a critical
role in host defense against infection and
in the activation of immunity. First, he145, May 13, 2011 ª2011 Elsevier Inc. 493
defined the pyrin domain, amotif similar in
structure to CARD and death domains,
which is expressed on a large family of
innate immune effector and regulatory
proteins. Ju¨rg was a prominent contrib-
utor to the cloning of members of both
the pyrin domain and the CARD domain
families. His landmark contribution in this
field was published in 2002 in Molecular
Cell, in which he defined a new molecular
entity he called the inflammasome. This
important complex mediates the signals
leading to activation of the pyrin domain—
carrying Nod-Like Receptor (NLR) pro-
teins through adaptor molecules such
as ASC, which can bind NLRs via its
pyrin domain and caspase-1 through its
CARD domain, leading to the activation
of caspase-1, which in turn proteolytically
processes and activates the inflammatory
cytokine interleukin-1. This exciting new
concept has been confirmed by both
targeted mutagenesis in mice as well
as the characterization of humans that
have mutant forms of these proteins
that lead to the spontaneous activation
of the inflammasome. Indeed, the recog-
nition of this mechanism of spontaneous
IL-1 production led to the now success-
ful therapy of these autoinflammatory494 Cell 145, May 13, 2011 ª2011 Elsevier Indiseases by the use of the IL-1 receptor
antagonist protein in the clinic.
Ju¨rg was inspired by the possibility of
making a difference in patients’ lives and
had the brilliant insight that uric acid crys-
tals activated the NLRP3 inflammasome
to cause the production of IL-1 and that
blocking this could be used as a basis of
therapy in the painful and mechanistically
puzzling disease of gout. By his own
force of will he convinced his medical
colleagues to establish this clinically with
dramatic and almost immediate effect.
In parallel to these great achievements,
he identified other platforms similar in
concept to the inflammasomes but that
play a role in sensing cellular stresses.
One of these, which he has called the
PIDDosome, acts as a sensor of geno-
toxic stress, detecting DNA damage and
orchestrating the activation of caspase-
2, or alternatively leads to NF-kB activa-
tion. Finally, Ju¨rg contributed importantly
to themolecular systems that identify viral
infection in the cellular cytoplasm by
identifying the RIG-I/cardif platform that
leads to a triggering of the interferon
antiviral response.
Ju¨rg authored well over 350 publica-
tions, many of which were published inc.top-line journals. More importantly, he
made major discoveries and introduced
several critical new concepts to the fields
of cell death and innate and adaptive
immunity. He was almost single-handedly
responsible for the introduction of the
inflammasome concept, which dominates
much of what we know of the innate
recognition of infection, and recently he
extended his studies to diseases associ-
ated with metabolic stress. His achieve-
ments were recognized with many
awards, including the Friedrich-Miescher
Award, the Max Cloe¨tta Award, the San
Salvatore Cancer Award, the European
Cell Death Organization Award, and the
Louis-Jeantet Prize.
Ju¨rgwas one of the leading biochemists
studying immunobiology of his genera-
tion. His science was like his sports play,
skillful and elegant, competitive yet scru-
pulously fair. His work was characterized
by the utmost of scientific and ethical
standards, and in thesecompetitive times,
he stood out as a paragon of fairness
coupled with scientific excellence. Ju¨rg
was both rigorous in his work and
generouswithmaterials that he generated
andwith acknowledgment of the contribu-
tions of others. He will be sorely missed.Richard A. Flavell1,*
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